Research | In Brazil, there are more than 1,500 researchers in universities, laboratories and research centers who are unable to get funding to create new molecules that will generate new medicines. Through confidentiality and partnership contracts, combined with a very well-developed mechanism for managing the stages of the phases provided for by Anvisa, Criptolabs is an active channel for aligning all the processes and generating the real, credible deadlines necessary for the development of nanotechnology molecules to store patents in all formats, both nationally and internationally.